Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Preparation and immune efficacy evaluation of inactivated lumpy skin disease virus vaccine.

Created on 14 Jul 2026

Authors

Xiaoqian Diao, Shaobing Wan, Jiaxu Lu, Xiangqian Zhang, Aoyun Li, Fang Liu, Haiju Dong, Kun Jia, Shoujun Li, Jingyu Wang

Published in

Veterinary research communications. Volume 50. Issue 5. Jul 14, 2026. Epub Jul 14, 2026.

Abstract

Lumpy Skin Disease (LSD), historically restricted to Africa, has in recent years exhibited a marked expansion into several Asian and European countries, resulting in substantial economic impacts on the global cattle industry. In August 2019, the first confirmed outbreak of LSD was documented in the Xinjiang region of China. In response to this emerging threat, our study established primary, basic, and working seed banks utilizing the LSDV/MZGD/2020 strain, which was isolated from Meizhou, Guangdong. These seed banks underwent rigorous validation via sterility assays and evaluation of proliferation characteristics. Optimal inactivation parameters for the virus were identified through systematic screening of different concentrations of β-propiolactone. Based on these optimized conditions, we developed two inactivated vaccine formulations: one employing the 201VG adjuvant and the other utilizing aluminum hydroxide adjuvant. Safety assessments demonstrated that both vaccines induced no significant irritation or adverse reactions in New Zealand rabbits and dairy cows, and that pathological examinations revealed no abnormal lesions. Immunogenicity analysis showed that the LSDV-201VG inactivated vaccine elicited robust and sustained serum neutralizing and specific antibody responses in cattle, with elevated antibody titers detected from weeks 4-5 and persisting for up to 8 weeks. In contrast, the vaccine formulated with aluminum hydroxide adjuvant generated relatively low antibody levels and failed to achieve requisite immunogenicity thresholds. Collectively, these results indicate that the LSDV-201VG inactivated vaccine exhibits high safety and immunogenic efficacy, providing a robust technical strategy for the prevention and control of LSD in China and Southeast Asia.

PMID:
42446614
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement